Table 5.
Projected expenditures by scenario: ADHD pharmacotherapy for children and adolescents in England and Germany, 2012
| Key projections1 | England | Germany | ||||
| Scenario | Low Extreme | Base Case | High Extreme | Low Extreme | Base Case | High Extreme |
| Expenditures 2012 | 49 m£ | 78 m£ | 117 m£ | 170 m€ | 311 m€ | 456 m€ |
| Increase 2012 over 2002 | +602% | +1,012% | +1,561% | +617% | +1,210% | +1,825% |
| Total CNS2 market (2012) | 2,039 mŁ(1,463 mŁ) | 2,068 m£ (1,492 m£) | 2,107 mŁ(1,531 mŁ) | 2,261 m€(1,585 m€) | 2,402 m€ (1,726 m€) | 2,547 m€(1,871 m€) |
| Share of total2 market (2012) | 2.4% (3.4%) | 3.8% (5.2%) | 5.5% (7.6%) | 7.5% (10.7%) | 12.9% (18.0%) | 17.9% (24.4%) |
| Projections by products | ||||||
| Stimulants | 40.7 m£ | 58.3 m£ | 91.3 m£ | 141 m€ | 259 m€ | 390 m€ |
| DEX | 0.6 m£ | 0.7 m£ | 1.2 m£ | n.a. | n.a. | n.a. |
| MPH-IR | 1.2 m£ | 1.5 m£ | 1.9 m£ | 5 m€ | 7 m€ | 8 m€ |
| MPH-MR | 22.3 m£ | 18.4 m£ | 24.4 m£ | 90 m€ | 74 m€ | 92 m€ |
| MPH-TDS | 6.7 m£ | 8.4 m£ | 14.2 m£ | 24 m€ | 36 m€ | 58 m€ |
| LisDEX | 10 m£ | 29.2 m£ | 49.6 m£ | 22 m€ | 143 m€ | 232 m€ |
| Nonstimulants | 8.6 m£ | 20.0 m£ | 25.5 m£ | 29 m€ | 51 m€ | 67 m€ |
| ATX | 8.6 m£ | 10.7 m£ | 13.7 m£ | 29 m€ | 39 m€ | 47 m€ |
| ARM | n.a. | 9.2 m£ | 11.8 m£ | n.a. | 13 m€ | 20 m€ |
1For abbreviations, see legend to Table 4. 2(share of) market for psychotropics (D) or CNS drugs (UK), calculated assuming a growth rate of 5% p.a. (figures in brackets represent one of the sensitivity analyses, indicating market shares assuming no growth of non-ADHD market segment); for comparison: share of market segment in 2002 was 0.77% (NHS, England) and 1.8% (GKV, Germany), respectively.